Brief: Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M
07/08/2025 16:13
Aug 7 (Reuters) - HUTCHMED (China) Ltd 0013.HK: UPDATES FY25 GUIDANCE FOR ONCOLOGY/IMMUNOLOGY CONSOL REVENUE TO $270 MILLION - $350 MILLION Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation